TY - JOUR
T1 - Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K/AKT/HIF-1α/cyclin D1 pathway
AU - Chen, J.
AU - Bai, M.
AU - Ning, C.
AU - Xie, B.
AU - Zhang, J.
AU - Liao, H.
AU - Xiong, J.
AU - Tao, X.
AU - Yan, D.
AU - Xi, X.
AU - Chen, X.
AU - Yu, Y.
AU - Bast, R. C.
AU - Zhang, Z.
AU - Feng, Y.
AU - Zheng, W.
N1 - Funding Information:
This work was supported by grants from the National Natural Science Foundation of China (grant numbers 81272883, 81202044, 81370074 and 81172478), the Science and Technology Commission of Shanghai Municipality (grant number 12ZR1447600), the Shanghai Municipal Public Health Bureau (grant number XYQ2013119) and the 'Chenxing Project' from Shanghai Jiao Tong University to ZZ. The role of YY in this project was partially supported by The National Foundation for Cancer Research and contributions from Stuart and Gaye Lynn Zarrow.
Publisher Copyright:
© 2016 Macmillan Publishers Limited All rights reserved.
PY - 2016/5/12
Y1 - 2016/5/12
N2 - Gankyrin is a regulatory subunit of the 26kD proteasome complex. As a novel oncoprotein, gankyrin is expressed aberrantly in cancers from several different sites and has been shown to contribute to oncogenesis in endometrial and cervical carcinomas. Neither gankyrin's contribution to the development of epithelial ovarian cancer nor its interaction with follicle-stimulating hormone (FSH)-driven proliferation in ovarian cancer has been studied. Here we have found that gankyrin is overexpressed in ovarian cancers compared with benign ovarian cystadenomas and that gankyrin regulates FSH upregulation of cyclin D1. Importantly, gankyrin regulates PI3K/AKT signaling by downregulating PTEN. Prolonged AKT activation by FSH stimulation of the FSH receptor (FSHR) promotes gankyrin expression, which, in turn, enhances AKT activation by inhibiting PTEN. Overexpression of gankyrin decreases hypoxia inducible factor-1α (HIF-1α) protein levels, but has little effect on HIF-1α mRNA levels, which could be attributed to gankyrin mediating HIF-1α protein stability via the ubiquitin-proteasome pathway. Reduction in HIF-1α protein stability led to attenuation of the binding with cyclin D1 promoter, resulted in abolishment of the negative regulation of cyclin D1 by HIF-1α, which promotes proliferation of ovarian cancer cells. Our results document that gankyrin regulates HIF-1α protein stability and cyclin D1 expression, ultimately mediating FSH-driven ovarian cancer cell proliferation.
AB - Gankyrin is a regulatory subunit of the 26kD proteasome complex. As a novel oncoprotein, gankyrin is expressed aberrantly in cancers from several different sites and has been shown to contribute to oncogenesis in endometrial and cervical carcinomas. Neither gankyrin's contribution to the development of epithelial ovarian cancer nor its interaction with follicle-stimulating hormone (FSH)-driven proliferation in ovarian cancer has been studied. Here we have found that gankyrin is overexpressed in ovarian cancers compared with benign ovarian cystadenomas and that gankyrin regulates FSH upregulation of cyclin D1. Importantly, gankyrin regulates PI3K/AKT signaling by downregulating PTEN. Prolonged AKT activation by FSH stimulation of the FSH receptor (FSHR) promotes gankyrin expression, which, in turn, enhances AKT activation by inhibiting PTEN. Overexpression of gankyrin decreases hypoxia inducible factor-1α (HIF-1α) protein levels, but has little effect on HIF-1α mRNA levels, which could be attributed to gankyrin mediating HIF-1α protein stability via the ubiquitin-proteasome pathway. Reduction in HIF-1α protein stability led to attenuation of the binding with cyclin D1 promoter, resulted in abolishment of the negative regulation of cyclin D1 by HIF-1α, which promotes proliferation of ovarian cancer cells. Our results document that gankyrin regulates HIF-1α protein stability and cyclin D1 expression, ultimately mediating FSH-driven ovarian cancer cell proliferation.
UR - http://www.scopus.com/inward/record.url?scp=84941670699&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84941670699&partnerID=8YFLogxK
U2 - 10.1038/onc.2015.316
DO - 10.1038/onc.2015.316
M3 - Article
C2 - 26364616
AN - SCOPUS:84941670699
SN - 0950-9232
VL - 35
SP - 2506
EP - 2517
JO - Oncogene
JF - Oncogene
IS - 19
ER -